48,470
edits
Difference between revisions of "P16"
Jump to navigation
Jump to search
→Use
(→Use) |
|||
| Line 25: | Line 25: | ||
*Squamous lesions of the [[uterine cervix]] - see [[HSIL]]. | *Squamous lesions of the [[uterine cervix]] - see [[HSIL]]. | ||
*Head and neck squamous cell carcinoma, specifically ''[[human papillomavirus-associated head and neck squamous cell carcinoma]]''. | *Head and neck squamous cell carcinoma, specifically ''[[human papillomavirus-associated head and neck squamous cell carcinoma]]''. | ||
===Head and neck squamous cell carcinoma=== | |||
p16 testing is useful in: | |||
#Lymph node metastases with an unknown primary. | |||
#Oropharyngeal carcinomas. | |||
Note: | |||
*Like elsewhere p16 is an imperfect surrogate marker for the presence of ''HPV''.<ref name=pmid23935769/> | |||
*Non-oropharyngeal sites (oral cavity, larynx, and hypopharynx) are not well-studied; however, it is known that p16 positivity is much less common in there.<ref name=pmid23935769>{{Cite journal | last1 = Stephen | first1 = JK. | last2 = Divine | first2 = G. | last3 = Chen | first3 = KM. | last4 = Chitale | first4 = D. | last5 = Havard | first5 = S. | last6 = Worsham | first6 = MJ. | title = Significance of p16 in Site-specific HPV Positive and HPV Negative Head and Neck Squamous Cell Carcinoma. | journal = Cancer Clin Oncol | volume = 2 | issue = 1 | pages = 51-61 | month = | year = 2013 | doi = 10.5539/cco.v2n1p51 | PMID = 23935769 }}</ref> | |||
==Positive== | ==Positive== | ||